Humanscape to Build the Finest Blockchain-based Patient Network in Asia

Food and Healthcare Press Releases Thursday August 2, 2018 15:03
SEOUL, South Korea--2 Aug--PRNewswire/InfoQuest
  • Direct sharing of symptoms and treatment processes and provision of compensation for the sharing of information.
  • Expected to release blockchain-based "Humanscape" later this year.

Today, more and more people are suffering from serious, incurable, and/or rare illnesses. However, access to information on such conditions has been quite limited, to hospitals or internet surfing. Even though there were communities and organizations serving people with certain illnesses, information was not widely available, due to the general nature of the illnesses.

Min-hoo Chang, the CEO of Humanscape, giving a speech at 'Blockchain Expo 2018' held in Amsterdam

Developing and implementing IT solutions in the healthcare sector for the past four years, Humanscape realized that there is a lack of proper health information platforms. They believed that providing an information exchange platform that gives patients complete control over their patients-generated health data (PGHD) and allowing pharmaceutical companies, doctors, and hospitals to utilize the data, will help us find new treatments and further improve existing treatments.

In addition, applying blockchain technology to such patient health data management will enable safe data exchange and storage. When patients record information on their illnesses via Humanscape, the information is encrypted and can only be used in designated areas. Additionally, patients will be compensated accordingly when they share information on the patient's platform. Min-hoo Chang, CEO of Humanscape, commented, "Since the simple act of sharing information can be so helpful for people suffering from rare and incurable diseases, we expect to see a high participation rate." Patients can exchange their compensation for cash. Humanscape Team is also planning on having various dApps (decentralized apps) to allow patients to purchase non-prescription, functional foods and medical equipment with its own currency earned as compensation.

The welcoming responses of patient organizations and pharmaceutical companies towards Humanscape exceeded its expectations. Chang commented, "Patient organizations that were in dire need of well-structured patients data have come to recognize the value of the Humanscape Project. Humanscape has signed MOUs with patient organizations for rare retina-related diseases, Korean Foundation Fighting Blindness and Amseungmo (one of the most well-known cancer patient communities), and is also discussing multi-faceted cooperation with many more." Chang also mentioned that, "Executives of global pharmaceutical companies that needed patient information on patients' medication, physical condition, and lifestyle, have joined Humanscape as advisors and are actively involved in the company's business activities."

Humanscape's long-term goal is to provide the best healthcare community service in Asia, especially in countries with poor medical services. To this end, the company has established a subsidiary in Indonesia and is currently establishing partnerships with local companies and hospitals. Furthermore, Humanscape is entering the Vietnamese market through the Ministry of SMEs and Startups' Global Expansion Program (GEP) with the support of the Chungnam Center for Creative Economy and Innovation.

Chang said, "There are relatively few patients with rare and incurable diseases, which makes it difficult for pharmaceutical companies to be active in this field. However, if a proper medicine is to be developed, it would be a blue ocean. In this context, if we are able to achieve our goal of creating the best patient community in Asia, I am certain that it will be beneficial to all."

Photo -
Caption: Min-hoo Chang, the CEO of Humanscape, giving a speech at 'Blockchain Expo 2018' held in Amsterdam

Latest Press Release

Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey

- Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey - Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to...

Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

ISABS เตรียมจัดการประชุมว่าด้วยการแพทย์ส่วนบุคคลที่โครเอเชีย พร้อมเชิญเจ้าของรางวัลโนเบลร่วมบรรยาย

International Society for Applied Biological Sciences (ISABS) ร่วมกับ Mayo Clinic และ St. Catherine Hospital เตรียมจัดการประชุม "ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine" ครั้งที่ 11...

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

International Society for Applied Biological Sciences (ISABS), Mayo Clinic and St. Catherine Hospital are organizing "11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine"(

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

Related Topics